Beijing, China · Founded 2016 · Privately Held (backing)
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. CHIGENOVO is based in Beijing, China and was founded in 2016. Its last reported valuation was $110 million in Mar 2022. It has raised $41 million.
Last reported valuation
$110.4M
Oct 2026
Priced at
—
Total raised
$41.0M
Last round
—
Cap table — not yet on record
CHIGENOVO's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of CHIGENOVO with a free account
·Watch CHIGENOVO: the Monday email on marks, rounds and moves
